Skip to main content

Search form

You are here

Emmanuel Benjamin Walter, MD

Professor of Pediatrics
Affiliate, Duke Global Health Institute
Member in the Duke Clinical Research Institute
Member of the Duke Human Vaccine Institute
Campus mail: 2608 Erwin Road, Suite 210, Durham, NC 27705
Phone: (919) 620-5374
Email address: walte002@mc.duke.edu

Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute.  In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.

Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID).  The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies.  He is the Duke Co-Principal Investigator for the NIAID Vaccine and Treatment Evaluation Unit (VTEU) which conducts clinical trials of vaccines and treatments for infectious diseases.  He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for a CDC-funded project to further understand and reduce disparities in vaccine coverage among rural adolescents.

Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine coverage, prevention and treatment of infectious diseases.

Education and Training

  • M.P.H., University of North Carolina - Chapel Hill, 1992
  • M.D., University of Maryland, College Park, 1983
  • B.S., University of Notre Dame, 1979

Selected Grants and Awards

Publications

Brady, Allison M., Emmanuel B. Walter, Lauri E. Markowitz, Elizabeth R. Unger, and Gitika Panicker. “Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity.” In Hum Vaccin Immunother, 16:1802–7, 2020. https://doi.org/10.1080/21645515.2019.1706410.

Full Text

Walter, Emmanuel B., and Robert L. Atmar. “Improving Influenza Prevention: Modest Changes With Large Effects.” Clin Infect Dis 70, no. 12 (June 10, 2020): 2503–4. https://doi.org/10.1093/cid/ciz683.

Full Text

Greenberg, Rachel G., Huali Wu, Anil Maharaj, Michael Cohen-Wolkowiez, Kay M. Tomashek, Blaire L. Osborn, Reese H. Clark, and Emmanuel B. Walter. “A Pharmacoepidemiologic Study of the Safety and Effectiveness of Clindamycin in Infants.” Pediatr Infect Dis J 39, no. 3 (March 2020): 204–10. https://doi.org/10.1097/INF.0000000000002524.

Full Text

Walter, Emmanuel B., Nicola P. Klein, A Patricia Wodi, Wes Rountree, Christopher A. Todd, Amy Wiesner, Jonathan Duffy, Paige L. Marquez, and Karen R. Broder. “Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations.” Pediatrics 145, no. 3 (March 2020). https://doi.org/10.1542/peds.2019-1909.

Full Text

Bernstein, David I., Jeffrey Guptill, Abdollah Naficy, Raffael Nachbagauer, Francesco Berlanda-Scorza, Jodi Feser, Patrick C. Wilson, et al. “Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.” Lancet Infect Dis 20, no. 1 (January 2020): 80–91. https://doi.org/10.1016/S1473-3099(19)30393-7.

Full Text

Keitel, W. A., D. C. Voronca, R. L. Atmar, S. Paust, H. Hill, M. C. Wolff, A. R. Bellamy, and A. R. VTEU H5N1 Vaccine Working Group. “Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis.” Vaccine 37, no. 37 (September 3, 2019): 5535–43. https://doi.org/10.1016/j.vaccine.2019.04.066.

Full Text

Grohskopf, Lisa A., Elif Alyanak, Karen R. Broder, Emmanuel B. Walter, Alicia M. Fry, and Daniel B. Jernigan. “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season.” Mmwr Recomm Rep 68, no. 3 (August 23, 2019): 1–21. https://doi.org/10.15585/mmwr.rr6803a1.

Full Text

Munoz, Flor M., Evan J. Anderson, David I. Bernstein, Christopher J. Harrison, Barbara Pahud, Edwin Anderson, C Buddy Creech, et al. “Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.” Vaccine 37, no. 36 (August 23, 2019): 5161–70. https://doi.org/10.1016/j.vaccine.2019.07.085.

Full Text

Hills, Susan L., Emmanuel B. Walter, Robert L. Atmar, Marc Fischer, and Marc ACIP Japanese Encephalitis Vaccine Work Group. “Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices.” Mmwr Recomm Rep 68, no. 2 (July 19, 2019): 1–33. https://doi.org/10.15585/mmwr.rr6802a1.

Full Text

Woods, Christopher W., Ana M. Sanchez, Geeta K. Swamy, Micah T. McClain, Lynn Harrington, Debra Freeman, Elizabeth A. Poore, et al. “An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults.” Vaccine 37, no. 30 (July 9, 2019): 4222–30. https://doi.org/10.1016/j.vaccine.2018.12.026.

Full Text

Pages